SIG
PHAS

Sargent Investment Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Sargent Investment Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,675
Closed -$30K – 205
2021
Q4 		$30K Buy
+11,675
New +$35.3K 0.01% 182

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
TCM
Towercrest Capital Management Newtown, Pennsylvania $642M AUM 11.71% 1-Year Est. Return
VPW
Vericrest Private Wealth Newtown, Pennsylvania $111M AUM

Sargent Investment Group's PHAS Position: Q1 2022 in Review

Sargent Investment Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 11,675 shares — an estimated $30K sold.

Sargent Investment Group first reported a position in PHAS in Q4 2021 and held it in 1 quarter. The position peaked at $30K in Q4 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

  • Sargent Investment Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Sargent Investment Group sold 11,675 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $30K.
  • Sargent Investment Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Sargent Investment Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $30K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Sargent Investment Group's 13F filing for Q1 2022, filed 6 May 2022.